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Abstract
Background: MicroRNA (miRNA) molecules are potent mediators of post-transcriptional gene silencing that are
emerging to be critical in the regulation of innate and adaptive immunity.
Results: Here we report that miR-155–an oncogenic miRNA with important function in the mammalian immune
system–is induced in dendritic cells (DCs) upon maturation and potentially attenuates their ability to activate
T cells. Biolistic epidermal transfection with DNA encoding miR-155 suppressed the induction of antigen-specific
T cell-mediated immunity, whereas reduction of endogenous miR-155 by a partially complementary antisense
sequence reversed this effect. Because DCs represent a significant component of epidermal tissue and are among
the most potent of antigen-presenting cells, the inhibitory actions of miR-155 could be mediated through this
subset of cells.
Conclusions: These results suggest that miR-155 may repress the expression of key molecules involved in lymph
node migration, antigen presentation, or T cell activation in DCs, and thus forms part of a negative regulatory
pathway that dampens the generation of T cell-mediated immune responses. Modulation of miR-155 expression in
epidermis therefore represents a potentially promising form of gene therapy for the control of diseases ranging
from autoimmunity to cancer and viral infection.
Background
The mammalian immune system exists in a state of
dynamic equilibrium, in which aggressive responses to
foreign pathogens are curtailed by intrinsic feedback
mechanisms that confer tolerance to self tissue. The
genes that maintain this equilibrium are exquisitely
regulated at the transcriptional level by intricate mole-
cular pathways that have gradually become revealed
over the past few years. However, the post-transcrip-
tional control of these genes remains to be understood.
Recently, it was discovered that multiple aspects of
cellular function are influenced by microRNA (miRNA),
a diverse class of small (~22 nucleotide) and copious
RNA species that efficiently ‘knocks down’ av a s t
array of genes at the post-transcriptional stage [1].
Collectively, these molecules are predicted to modulate
the expression of many human genes. miRNA is initially
produced as a ~60 nucleotide precursor with a defined
stem-loop structure. Following nuclear export, it is pro-
cessed by the enzyme Dicer into a ~22 nucleotide
duplex, and a single strand is then preferentially incor-
porated into the RNA-induced silencing complex
(RISC). The miRNA-RISC binds to partially comple-
mentary sites in the 5’ or 3’ untranslated regions (UTR)
of target mRNA molecules, where it induces either
translational repression or mRNA degradation.
Several recent reports have demonstrated that miRNAs
exert profound effects on the development and function of
innate and adaptive immunity (for review, see [2]). Recent
studies have shown that miRNAs can control maturation,
function, and maintenance of dendritic cells [3-5]. Based
on these findings, we were interested in whether miRNA
expression in dendritic cells (DCs), highly potent profes-
sional antigen-presenting cells, impacts their ability to
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any medium, provided the original work is properly cited.activate naïve T cells. We chose to study a recently discov-
ered miRNA, miR-155–which is encoded by exon 3 of the
bic gene–since evidence suggests that it is intimately
involved in regulation of multiple arms of the immune sys-
tem [6,7]. Rodriguez et al. demonstrated that transgenic
mice carrying an inactivating mutation in bic were unable
to protect against challenge with Salmonella typhimurium
despite pre-vaccination with a nonvirulent strain of these
bacteria [7]. Further analysis revealed that these bic-
deficient (bic
m/m) mice had reduced numbers of IgM
class-switched antigen-specific antibodies, and interferon
(IFN)-g and interleukin (IL)-2 secretion by activated
T cells was impaired, indicating that miR-155 is broadly
indispensable for normal immunological function [7]. By
contrast, a recent study has reported that miR-155 attenu-
ates the inflammatory pathway induced by IL-1 in vitro
[8]. Thus, the function of miR-155 in the physiologic set-
ting, and specifically whether it acts to propagate or sup-
press the adaptive immune response, is presently unclear.
We hypothesized that–due to the pleiotropic effects of
miR-155 on the immune system established in previous
studies–its expression in DCs may modulate the strength
of T cell priming. In this context, we sought to clarify the
in vivo role of miR-155 in influencing DC-mediated T cell
activation.
Here we show that miR-155 is induced in murine
bone marrow-derived DCs (BMDCs) upon stimulation
with the Toll-like receptor (TLR) 4 ligand lipopolysac-
charide (LPS), and that its expression attenuates T cell
activation in vivo. Conversely, reduction of endogenous
miR-155 levels with a partially complementary antisense
sequence augmented the induction of antigen-specific
T cells. Our data suggest that miR-155 expression in acti-
vated DCs may be involved in the repression of genes
required for antigen presentation or T cell stimulation.
Thus, miR-155 may constitute part of a negative regula-
tory system that evolved to temper the magnitude of the
adaptive immune response and protect against the onset
of autoimmune pathologies.
Results
DCs express detectable levels of endogenous miR-155
To determine whether miR-155 has biological signifi-
cance in DCs, we first assayed for endogenous expres-
sion of this miRNA in BMDCs stimulated with the
TLR4 agonist LPS. Endpoint RT-PCR was then per-
formed using small RNA isolated from BMDCs with pri-
mers specific for miR-155. As shown in Figure 1, a band
was observed at ~90 base pairs in the LPS-pulsed
BMDC RNA-loaded lane. The location of this band is
consistent with the approximate expected size of the
RT-PCR-amplified miRNA product, indicating that
miR-155 is present in activated DCs. Significantly, no
miR-155 was observed in BMDCs left untreated with
LPS, suggesting that this miRNA is induced upon
maturation and thus may play an important role in the
inflammatory response. The DC-1 and 293T cell lines
were assessed for miR-155 expression as positive and
negative controls, respectively.
A DNA vector that encodes miR-155, bic
155, efficiently
silences expression of a reporter construct that contains
an miR-155 complementary sequence
Because miR-155 is strongly induced in DCs upon
maturation, we sought to determine whether its expres-
sion holds immunological significance. In this context,
we synthesized a DNA vector that encodes an active
form of miR-155 in order to modulate its expression in
DCs and study how it influences their ability to prime
naïve antigen-specific T cells. Chung et al.h a v ep r e -
viously shown that the nucleotide sequence 134-283
from exon 3 of the bic gene is the minimal segment
necessary to achieve strong expression and activity of
miR-155 [9]. This sequence contains the miR-155 stem-
loop flanked by portions required for efficient miRNA
processing to the mature form. We generated a mam-
malian expression vector encoding nucleotide sequence
134-283 from exon 3 of bic to generate bic
155 (Figure
2A, top). In order to characterize the knockdown capa-
city of bic
155, a reporter construct was created by insert-
ing a sequence perfectly complementary to the mature
form of miR-155 into the 3’ UTR of the green fluores-
cence protein (GFP) gene to form GFP/miR-155as
(Figure 2A, bottom). We expected that cells transfected
with GFP/miR-155as should display high levels of GFP
expression, which would be significantly reduced by the
introduction of the bic
155 construct due to the targeted
knockdown of the GFP reporter.
Figure 1 Characterization of miR-155 expression in BMDCs
using RT-PCR. Total RNA was purified from 1 × 10
7 cultured
BMDCs and enriched for small RNA species. Endpoint RT-PCR was
then performed using primers directed against miR-155 to detect
the presence of this miRNA in DCs. Expression of GAPDH was also
tested to validate the assay. RNA from DC-1 and HEK 293 cells was
used as a positive and negative control, respectively.
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and either bic
155 or a control construct encoding non-
specific miRNA. The cells were visualized by fluores-
cence microscopy 24 hrs after transfection. As shown in
Figure 2B, cotransfection with bic
155 (panel II) compared
to control (panel I) strongly reduced GFP expression
from the GFP/miR-155as vector. There was no notice-
able difference in cellular viability or proliferation
between these groups, and transfection efficiency
appeared uniform as assessed by flow cytometry (data
not shown). Thus, bic
155 represents a DNA vector that
efficiently produces functional miR-155 in mammalian
DCs. Furthermore, as evident in panels III and IV, trans-
fection with bic
155 does not alter GFP expression from
a reporter construct in which the miR-155 target
sequence is abolished (GFP/control), confirming the
specificity of our construct.
To determine the extent to which the endogenous
miR-155 in DC-1 cells may have contributed to the
observed knockdown effect, we compared the fluores-
cence intensity in cells transfected with small amounts
of either GFP/control or GFP/miR-155as. It was found
that GFP expression was not significantly, reduced in
cells transfected with GFP/miR-155as (panel V) relative
to GFP/control (panel III). Altogether these data indi-
cate that introduction of bic
155 in our in vitro system
dramatically increases the expression of functional miR-
155 over basal levels.
Coadministration of CRT/E7 DNA vaccine with bic
155
attenuates E7-specific T cell-mediated immune responses
in vaccinated mice
Next we aimed to determine whether bic
155 expression
in DCs has functional significance and can influence the
Figure 2 Generation and characterization of the knockdown efficiency of bic
155, a mammalian expression vector encoding miR-155. A,
Schematic diagrams to show bic
155 (top), a construct containing nucleotides 134-283 of exon 3 of the bic gene, and GFP/miR-155as (bottom), a
reporter construct containing a sequence perfectly antisense to miR-155 in the 3’ UTR of GFP. B, Fluorescence microscope image at 24 hrs of
DC-1 cells transfected with GFP/miR-155as in combination with either bic
155 (panel I) or a control construct encoding non-specific miRNA (panel
II). GFP/miR-155as and bic
155 transfection complexes were formulated in Lipofectamine 2000 in a 1:9 mass ratio. The knockdown efficiency of
bic
155 was measured as the relative difference in fluorescent intensity between the two groups. For further characterization of bic
155, DC-1 cells
were also transfected with GFP/control (panel III), GFP/control and bic
155 (panel IV), or GFP/miR-155 (panel V).
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shown that epidermal DCs in mice can be efficiently
transfected by intradermal DNA administration using
t h eg e n eg u n ,ab i o l i s t i cp a r t i c l ed e l i v e r ys y s t e m[ 1 0 ] .
These transfected DCs are activated by the pressure
from bombardment and undergo migration to periph-
eral lymphoid organs. In fact, they have been found to
constitute approximately 0.2% of CD11c
+ cells in the
inguinal lymph nodes and persist there for at least
5 days [11]. Our laboratory has previously developed a
chimeric DNA vaccine encoding the molecular chaper-
one calreticulin linked to the E7 oncoprotein of human
papillomavirus type-16 (CRT/E7) and demonstrated that
vaccination with CRT/E7 can elicit potent CD8
+ T cell-
mediated immunity against E7 [12]. We thus utilized
this vaccination system to generate antigen-specific
Tc e l l sin vivo, and investigated how the magnitude of
these responses might be modulated when bic
155 is
coadministered with CRT/E7 into mice by gene gun.
C57BL/6 mice were intradermally administered with
CRT/E7 in combination with either bic
155 or a control
construct. Animals were boosted with the same dose and
regimen on day 7. Splenocytes were harvested on day 14
and cultured for 15 hrs in the presence or absence of E7
peptide. Cells were then costained for intracellular IFN-g
and surface CD8 and subsequently analyzed by flow cyto-
metry. As demonstrated in Figure 3A, coadministration
with bic
155, compared to control, greatly decreased the
number of IFN-g-secreting, E7-specific CD8
+ Tc e l l s
induced by CRT/E7. As expected, splenocytes in both
vaccination groups not pulsed with E7 peptide contained
negligible numbers of IFN-g-secreting, E7-specific CD8
+
T cells. Figure 3B is a bar graph representation of the
data (* p < 0.005). Our data suggest that miR-155 med-
iates an important immunosuppressive function in DCs,
perhaps through the post-transcriptional knockdown of
molecules that are central to T cell activation.
A DNA vector that encodes an antisense RNA sequence
partially complementary to miR-155, I
155, rescues the
expression of GFP in DCs cotransfected with Bic
155 and
GFP/miR-155as
We reasoned that, if miR-155 expression in DCs indeed
negatively regulates T cell activation, then reducing
Figure 3 Characterization of the number of E7-specific IFN-g CD8
+ T cells in mice vaccinated intradermally with CRT/E7 DNA in
combination with either bic
155 or a control construct. A, C57BL/6 mice (3 per group) were immunized with CRT/E7 DNA in combination
with either bic
155 (left panels) or a control construct (right panels). At day 7, animals received boosters at the same dose and regimen. At day 14,
splenocytes were harvested, cultured for 15 hrs with (top panels) or without (bottom panels) E7 peptide, and stained for surface CD8 and
intracellular IFN-g. Cells were analyzed by flow cytometry. The top right quadrant in each dot plot indicates the number of IFN-g-secreting E7-
specific CD8
+ T cells. B, Bar graph representation of the flow cytometry data (mean ± SD).
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site effect. To further explore this possibility, we gener-
ated a DNA vector that encodes an antisense RNA
sequence partially complementary to miR-155 and
examined whether it would, as predicted, exhibit a
potentiating effect on T cell activation when coadminis-
tered with CRT/E7.
Ebert et al. have recently demonstrated that partially
complementary antisense RNA sequences may serve as
competitive inhibitors of miRNA [13]. Based on this find-
ing, we designed a mammalian expression vector which
contains 6 tandemly repeated miR-155 partially antisense
regions cloned into the 3’ UTR of the red fluorescence
protein (RFP) gene to generate I
155.F i g u r e4 As h o w sa
schematic diagram of I
155. The miR-155 partially antisense
regions have been shown to bind stably to miR-155-RISC
and form bulges at the site normally cleaved by Argonaute-
2, the catalytic component of RISC, effectively protecting
I
155 from degradation by the cellular RNA interference
machinery [13]. Furthermore ,t h ep r e s e n c eo fm u l t i p l e
partially antisense repeats has been shown to enhance the
avidity between I
155 and miR-155-RISC and enables this
miRNA inhibitor to successfully outcompete endogenous
miR-155 target genes [13]. I
155 contains the RFP gene
to facilitate verification of its transfection efficiency as well
as the intracellular stability of its encoded RNA.
We sought to determine whether the expression of
I
155 can inhibit the activity of miR-155 in transfected
Figure 4 Generation and characterization of the ability of I
155, a mammalian expression vector encoding sequences partially antisense
to miR-155, to restore GFP expression in a DC line cotransfected with bic
155and GFP/miR-155as. A, Schematic diagram to depict I
155,a
DNA plasmid construct that contains 6 tandemly repeated sequences partially antisense to miR-155 cloned into the 3’ UTR of red fluorescent
protein. The partially complementary sequences of I
155 shown in the diagram bind imperfectly to miR-155 to form a 4-nucleotide mismatched
bulged site and may serve as a competitive inhibitor of miR-155. B, Fluorescence microscope image at 24 hrs of DC-1 cells transfected with GFP/
miR-155as in combination with a control construct encoding non-specific miRNA (panel I), bic
155 (panel II) or both bic
155 and I
155 (panels III and
IV). The empty pcDNA3 vector was used to standardize the total amount of transfected DNA. GFP/miR-155as and bic
155 transfection complexes
were formulated in Lipofectamine 2000 in a 1:9 mass ratio. The transfection efficiency of I
155 was measured by the red fluorescent intensity
(panel V) and the degree to which I
155 restored GFP expression in bic
155- and GFP/miR-155as-cotransfected cells (panel IV). To further characterize
the I
155 construct, DC-1 cells were transfected with 0.1 μg of either RFP/control (panel V) or I
155 (panel VI).
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cells with GFP/miR-155as generated a strong green
fluorescent signal in these cells, which was markedly
diminished by introduction of bic
155.I nt h e o r y ,i f
expression of I
155 leads to the knockdown of miR-155,
then treatment of cells with I
155 should rescue GFP
expression in cells cotransfected with GFP/miR-155as
and bic
155.
DC-1 cells were transfected with GFP/miR-155as
alone or in combination with either bic
155 or both bic
155
and I
155. Cells were imaged by fluorescence microscopy
24 hrs after transfection. As illustrated in Figure 4B,
green fluorescence was observed in cells cotransfected
with GFP/miR-155as and a control construct encoding
non-specific miRNA (panel I), whereas it was virtually
undetectable in cells also cotransfected with GFP/miR-
155as and bic
155 (panel II), confirming previous observa-
tions that bic
155 exerts a dramatic knockdown effect on
miR-155 target gene expression (see Figure 2B). Further,
we observed that transfection of DC-1 cells with I
155
together with GFP/miR-155as and bic
155 restored the
expression of GFP (panel IV). The transfection efficiency
of I
155 in DC-1 cells was demonstrated by the expres-
sion of RFP (panel III). There was no noticeable differ-
ence in cellular viability or proliferation between all
these groups, and transfection efficiency appeared uni-
form as assessed by flow cytometry (data not shown).
Therefore, our data suggest that I
155 acts as a highly effi-
cient inhibitor of miR-155.
Because the I
155 construct contains 6 tandemly
repeated sites partially complementary to miR-155, it is
conceivable that–in addition to its role as an inhibitor–
it could also serve as a target for endogenous miR-155,
and its expression could be suppressed at the post-
transcriptional level. To test this possibility, we com-
pared red fluorescence intensity in DCs transfected with
a small amount of either I
155 or an RFP vector with the
miR-155 antisense sequences abolished (RFP/control).
As shown in Figure 4B, cells transfected with I
155 (panel
VI), relative to RFP/control (panel V), displayed substan-
tially decreased RFP expression, although this difference
in expression could be due to variation in the nature of
the DNA constructs. There was no observable difference
in confluence or transfection efficiency between the
groups. Thus, we have demonstrated that I
155 potently
attenuates the expression and function of miR-155 in
DCs and itself serves as a target of the endogenous form
of this miRNA.
Coadministration of I
155 with CRT/E7 DNA enhances E7-
specific CD8
+ T cell-mediated immune responses in
vaccinated mice
We hypothesized that, since bic
155 strongly attenuated the
T cell-mediated immune response in CRT/E7-vaccinated
mice, an inhibitor of miR-155, I
155,w o u l dr e v e r s et h i s
effect. C57BL/6 mice were intradermally administered by
gene gun with CRT/E7 in combination with bic
155, I
155,o r
a control construct. Animals were boosted with the same
dose and regimen on day 7. Splenocytes were harvested
on day 14 and then characterized for E7-specific CD8
+ T
cell-mediated immune responses by intracellular IFN-g
and surface CD8 staining followed by flow cytometry ana-
lysis. As shown in Figure 5, while coadministration of
bic
155 with CRT/E7 DNA decreased the number of IFN-g-
secreting E7-specific cytotoxic T cells generated by CRT/
E7 (* p < 0.01), coadministration of I
155 with CRT/E7
DNA significantly improved the E7-specific CD8
+ T cell-
mediated immune response generated by CRT/E7 (** p <
0.05). Altogether, our data indicate that modulation of
expression levels of miR-155 can influence the ability of
DCs to prime antigen-specific naïve T cells in vivo.
Furthermore, these results suggest that miR-155 may act
broadly as a post-transcriptional silencer in negative feed-
back pathways that dampen the adaptive immune
response following the initial phases of T cell activation.
Discussions
In the current study, we have provided data to demon-
strate that miR-155 is induced in DCs upon maturation
and that its expression in vivo negatively regulates the
induction of antigen-specific T cells. Administration of
bic
155, a miR-155 expression vector, to epidermal DCs
in vivo suppressed the generation of T cell-mediated
immunity. This outcome was reversed by decreasing
endogenous miR-155 levels in DCs with a partially anti-
sense inhibitor, I
155. These results altogether suggest
that miR-155 has an inhibitory effect on DC-mediated
T cell activation. In addition, our data also suggest that
miRNA levels in DCs may be manipulated to modulate
the activation of antigen-specific T cell-mediated immu-
nity for therapeutic purposes.
Our findings reveal a new way in which miRNAs may
exert control over the immune system. The role of miR-
NAs as key regulators of the innate and adaptive
immune systems is becoming increasingly evident.
Indeed, miRNAs have recently been implicated in a
wide variety of immunological processes, including
hematopoietic cell differentiation [14], lymphocyte
development and function [6,7,15-17], as well as protec-
tive responses against bacterial [18] or viral [19] patho-
gens. The current study identifies a novel role of
miRNA in the regulation of DC-mediated antigen-speci-
fic T cell priming.
In general, the expression of miRNAs is precisely con-
trolled at the transcriptional level, enabling them to
finely adjust cellular behavior as necessary. miR-155
production is believed to be transiently under the con-
trol of nuclear factor (NF)-Ba n dc a nb es t r o n g l y
Mao et al. Cell & Bioscience 2011, 1:3
http://www.cellandbioscience.com/content/1/1/3
Page 6 of 11induced during inflammation [18,20,21]. Recently, miR-
155 has also been shown to play a role in the promotion
of T cell-dependent tissue inflammation [22]. It has
been shown that basal miR-155 levels in murine macro-
phages are virtually undetectable but increase dramati-
cally by 6 hrs after treatment with the TLR ligands
polyriboinosinic:polyribocytidylic acid (poly(I:C)), LPS,
CpG, and P3C, as well as the cytokines IFN-b and IFN-
g, in a c-Jun N-terminal kinase-dependent manner
[18,20]. We have demonstrated that this phenomenon is
conserved in DCs, as stimulation of these cells with LPS
strongly induced miR-155. Collectively, our findings sug-
gest that miR-155 expression may be a global conse-
quence of inflammation, although the precise role it
plays in this process may vary depending on cell type.
It has been demonstrated that miR-155 is critical for
the generation of robust T cell-mediated immunity in
mice, partly through the action of this miRNA in DCs
[7]. In this context, we were surprised to find that
coadministration of DNA encoding miR-155 with
CRT/E7 led to a decrease in E7-specific CD8
+ T cell-
mediated immune responses in vivo. These results sug-
gested to us that miR-155 may have a complicated
function in DCs, in which its influence on T cell sti-
mulatory capacity could vary depending on its expres-
sion level or the developmental stage of the cell.
Alternatively, because our biolistic delivery method
transfects a wide variety of epidermal cells in addition
to DCs, it is conceivable that the phenomenon we
observed is due to the effects of miR-155 on these
other types of cells. We reasoned that if overexpression
of miR-155 in DCs diminished antigen-specific T cell
responses, then suppression of this miRNA should
correspondingly augment these responses. Biolistic
delivery to epidermal DCs of an efficient miR-155
repressor, I
155, significantly amplified the number of
IFN-g-secreting E7-specific CD8
+ T cells generated by
the CRT/E7 vaccine. Therefore, manipulation of endo-
genous miR-155 levels in DCs alters the intensity of
DC-induced T cell-mediated immunity in vivo in a sys-
tematic manner, consistent with the proposed immu-
nosuppressive activity of this miRNA.
Figure 5 Characterization of the number of E7-specific IFN-g CD8
+ T cells in mice vaccinated intradermally with CRT/E7 DNA in
combination with bic
155 , I
155, or a control construct. C57BL/6 mice (3 per group) were immunized with CRT/E7 in combination with bic
155,
I
155, or a control construct. At day 7, animals received boosters at the same dose and regimen. At day 14, splenocytes were harvested, cultured
for 15 hrs with (black bars) or without (grey bars) E7 peptide, and stained for surface CD8 and intracellular IFN-g. Cells were analyzed by flow
cytometry. A, Representative flow cytometry data depicting the number of E7-specific CD8
+ T cells. B, Bar graph representation of the flow
cytometry data (mean ± SD). The y-axis on the bar graph depicts the number of IFN-g-secreting E7-specific CD8
+ T cells per 3 × 10
5 counted
splenocytes (mean ± SD).
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function of miR-155 as an attenuator of the adaptive
immune system and provide clues about the molecular
mechanisms through which this miRNA exerts its
effects. It was recently shown that the NF-B signaling
pathway may be repressed by miR-155 through the
silencing of inhibitor of NF-B( I B) kinase (IKK) ε
[23]. In response to TLR signaling, the IKK family of
proteins phosphorylates IB, thereby enabling NF-Bt o
translocate into the nucleus and initiate transcription.
IKKε has also been demonstrated to facilitate NF-B
nuclear import by phosphorylating its c-Rel subunit
[24]. In addition, IKKb as well as a variety of other cen-
tral immunological molecules–such as Fas-associated
death domain protein (FADD) and receptor (TNFRSF)-
interacting serine-threonine kinase 1 (Ripk1)–likely
represent major direct targets of miR-155 [21]. FADD is
an adaptor molecule that is crucial for the development
of normal immune responses [25,26], and Ripk1 med-
iates tumor necrosis factor-induced activation of NF-B
[27]. Therefore, since the maturation and T cell stimula-
tory capacity of DCs depends vitally on signaling
through the NF-B pathway, miR-155 could exert its
inhibitory effects by suppressing this pathway on multi-
ple levels. Furthermore, a recent study has reported that
miR-155 produced by human monocyte-derived DCs
attenuates the TLR/IL-1 pathway and silences trans-
forming growth factor-b activated kinase 1 binding pro-
tein (TAB2), an important intermediate in the IL-1
cascade [8]. This in vitro evidence directly supports our
results which suggest that miR-155 expression in DCs is
part of a negative feedback loop that suppresses the
inflammatory response. While we believe, on the basis
of its likely molecular targets, that miR-155 influences
DC biology primarily at the level of antigen presentation
and processing or costimulation, we cannot exclude the
possibility that the in vivo effects we observed in this
study were at least partially due to other factors, such as
the potential ability of miR-155 to impair cellular migra-
tion to the peripheral lymphoid organs. These alterna-
tive mechanisms present an important area for future
investigation.
On the basis of our current data and the work of
others, it is intriguing to speculate about the purpose of
miR-155 activity in DCs. We propose a dose-dependent
paradigm in which a threshold miR-155 expression level
must be maintained in DCs in order to generate effec-
tive T cell-mediated immunity against foreign patho-
g e n s .H o w e v e r ,w h e ne n v i r o n mental stimuli cause the
concentration of cellular miR-155 to escalate beyond
this basal level, miR-155 becomes sufficiently abundant
to repress the translation of molecules involved in anti-
g e np r e s e n t a t i o no rTc e l la c t i v a t i o n ,a n dt h u sm a y
form part of a negative regulatory pathway that restrains
t h em a g n i t u d eo ft h ea d a p t i v ei m m u n er e s p o n s ea n d
perhaps evolved to protect against the onset of autoim-
mune pathologies.
The current study mainly focuses on an immature DC
line, DC-1. It will be important to also consider per-
forming experiments to interfere with miR-155 levels
during different maturation stages of monocyte-derived
DCs (moDCs) for a more comprehensive understanding
of the effect of miR-155 on the biological function of
moDCs [28]. However, the potential limitations for such
an experimental approach is the overexpression of miR-
NAs to non-physiological levels that may lead to altered
target genes. Thus it is important to consider the
expression levels of miRNAs in moDCs for gain- or
loss-of-function studies to illustrate the influence of
miR-155 on moDCs.
Finally, this study provides an impetus and framework
for the development of miRNA-based therapeutics. To
our knowledge, this is the first report of in vivo miRNA
delivery for the modulation of adaptive immunity. We
have demonstrated the general principle that miRNAs
or their inhibitors can be biolistically administered into
epidermal DCs to systematically manipulate T cell-
mediated immune responses. It is exciting to envision
the possibility that, in the near future, these small yet
powerful RNA species may be incorporated into medi-
cines for autoimmune disorders or into vaccines for
cancers and viral infections.
Conclusions
Taken together, our results suggest that miR-155 may
repress the expression of key molecules involved in lymph
node migration, antigen presentation, or T cell activation
in DCs, and thus forms part of a negative regulatory path-
way that dampens the generation of T cell-mediated
immune responses. Modulation of miR-155 expression in
DCs therefore represents a potentially promising form of
gene therapy for the control of diseases ranging from auto-
immunity to cancer and viral infections.
Methods
Preparation of BMDCs
Bone marrow cells were flushed from tibiae and femurs
of C57BL/6 mice. After lysis of erythrocytes, cells were
washed twice and resuspended at 1 × 10
6 cells/ml in
RPMI-1640 medium supplemented with 2 mM gluta-
mine, 1 mM sodium pyruvate, 100 μM nonessential
amino acids, 5 × 10
-5 M b-mercaptoethanol, 100 IU/ml
penicillin, 100 μg/ml streptomycin, 5% fetal bovine
serum, and 20 ng/ml recombinant murine GM-CSF
(PeproTech, Rock Hill, NJ). Cells were cultured in 24-
well plates at 37°C in a humidified incubator with 5%
CO2. On days 2 and 4, cells were replenished with fresh
medium supplemented with 20 ng/ml GM-CSF. On day
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untreated and then harvested for RNA isolation and
RT-PCR.
miRNA isolation and detection
Total RNA was purified from 1 × 10
7 BMDCs by acid-
phenol:chloroform extraction using the mirVana miRNA
Isolation Kit (Ambion, Austin, TX). The resultant sam-
ple was enriched for small RNA species by ethanol pre-
cipitation according to the manufacturer’s instructions.
Endpoint RT-PCR was then performed with primers
directed against either mature miR-155 or the house-
keeping gene GAPDH using the mirVana qRT-PCR
miRNA Detection Kit (Ambion). In order to facilitate
the PCR, the miR-155 RT primer was designed to intro-
duce a flanking sequence which extends beyond the 5’
region of the mature form of this miRNA. Therefore,
the final amplified product is about 90 base pairs. As a
positive control, we used DC-1 cells, which are derived
from an immortalized DC line [29] kindly provided
by Dr. Kenneth Rock (University of Massachusetts,
Worcester, MA) and constitutively produce miR-155. As
a negative control, we used the human embryonic
kidney cell line 293. Tissue from kidney has previously
been shown to lack miR-155 [6].
Plasmid expression vectors
For the generation of bic
155, nucleotides 134-283 from
exon 3 of the bic gene were synthesized (GeneArt,
Regensburg, Germany) with flanking XbaI and EcoRI
restriction sites and cloned into the pcDNA3.1(-)
mammalian expression vector (Invitrogen, Carlsbad,
CA). GFP/miR-155as was created by ligating an oligo-
nucleotide (5’-CCCCTATCACAATTAGCATTAA-3’)
perfectly antisense to mature miR-155 into the
BamHI/HindIII sites of the pcDNA3.GFP plasmid [30].
A miRNA control DNA construct was generated in
which a non-specific miRNA was cloned into the
pcDNA3 plasmid. This control construct is not
expected to hybridize with miR-155 target sites. GFP/
control represents the GFP/miR-155as construct with
t h em i R - 1 5 5b i n d i n gs i t ed e l e t e d .F o rt h ep r o d u c t i o n
of I
155, 6 tandemly repeated DNA fragments of imper-
fect complementarity (5’-CCCCTATCACGAAAGCAT-
TAA-3’) to mature miR-155 were synthesized with 4
guanine nucleotide spacers in between each one. These
sequences were then inserted into the 3’ UTR (at
BamHI/HindIII sites) of pcDNA3.RFP. RFP/control
represents the I
155construct with the miR-155 anti-
sense region deleted. The design of the CRT/E7 con-
struct has been reported previously [12]. Plasmids were
confirmed by DNA sequencing.
Cell culture and DNA transfection
By continuous passage we generated a subclone (DC-1)
of an immortalized DC line, [29] that is readily trans-
fectable with Lipofectamine 2000 (Invitrogen). DC-1
cells were cultured in RPMI-1640 (Sigma-Aldrich, St.
Louis, MO) at 37°C in a humidified incubator with 5%
CO2.5×1 0
5 cells/well were seeded in 6-well plates, and
transfections were performed using Lipofectamine 2000
(Invitrogen) with combinations of GFP/miR-155as,
bic
155,a n dI
155 in a 1:9:10 mass ratio. Empty pcDNA3
vector was added to standardize the total amount of
DNA in each group to 10 μg. 24 hrs after transfection,
cells were visualized by fluorescence microscopy.
Mice
6- to 8-week old female C57BL/6 mice were purchased
from the National Cancer Institute (Frederick, MD) and
housed in the animal facility at CRBII, Johns Hopkins
School of Medicine (Baltimore, MD). All procedures
were performed in accordance with established proto-
cols and recommendations for the proper use and care
of laboratory animals.
Biolistic DNA delivery in vivo
DNA-coated gold particles were prepared and delivered
b yah e l i u m - d r i v e ng e n eg u n (BioRad, Hercules, CA)
using a method published previously. [31] 0.2 μgo f
CRT/E7 in combination with 1.8 μgo fbic
155, I
155,o ra
control construct were administered to the shaved
abdominal region of C57BL/6 mice (3 per group) at a
discharge pressure of 400 psi. Mice were boosted at day
7 with the same dose and regimen. At day 14, the ani-
mals were sacrificed, and their spleens were explanted
for further analysis.
Flow cytometry
Splenocytes harvested from DNA-bombarded mice were
pooled and seeded at 1 × 10
7 cells/well in 24-well
plates. Cells were incubated for 15 hrs in the presence
of GolgiStop (Pharmingen, San Diego, CA) with or
without 1 μg/ml E7 peptide (amino acids 49-57). Cells
were then washed in FACScan buffer, and surface mar-
ker detection of CD8 and intracellular cytokine staining
for IFN-g were performed as described [31]. Samples
were analyzed on a Becton Dickinson FACSan Flow
Cytometer with CellQuest software (BD Biosciences,
San Jose, CA).
Statistical Analysis
Data presented as mean ± standard deviation are repre-
sentative of at least two different experiments. All
p-values < 0.05 were considered significant. Statistical
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ples with SigmaPlot (Systat software, Inc., San Jose, CA).
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